To achieve negative intraoperative margins as much as possible, when tumor resection is limited, patients with defined tumor subtypes may benefit from gene-targeted therapy with PDGFRA or MDM2, especially for those with less differentiated IS. Here, PDGFRA is linked to neoplasm.